Royal Bank Of Canada Has Lowered Expectations for Alkermes (NASDAQ:ALKS) Stock Price

Alkermes (NASDAQ:ALKS) had its target price reduced by equities researchers at Royal Bank Of Canada from $47.00 to $45.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 49.14% from the company’s previous close.

Several other research firms also recently issued reports on ALKS. Bank of America boosted their price target on Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Wells Fargo & Company cut their target price on Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Wolfe Research assumed coverage on shares of Alkermes in a report on Monday. They set an “outperform” rating and a $45.00 price target on the stock. Truist Financial raised their price objective on Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, November 17th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.07.

Alkermes Stock Performance

Alkermes stock traded down $0.87 during mid-day trading on Thursday, reaching $30.17. The company’s stock had a trading volume of 745,544 shares, compared to its average volume of 2,004,099. Alkermes has a 12 month low of $25.17 and a 12 month high of $36.32. The business’s 50 day simple moving average is $31.44 and its 200 day simple moving average is $30.17. The company has a market capitalization of $4.98 billion, a price-to-earnings ratio of 14.93 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the prior year, the company earned $1.05 earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, sell-side analysts expect that Alkermes will post 1.31 EPS for the current year.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at approximately $1,959,118.20. The trade was a 13.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Shane Cooke sold 61,200 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. This represents a 37.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 148,148 shares of company stock valued at $5,028,378. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after acquiring an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Alkermes in the 1st quarter valued at $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Alkermes by 4.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock valued at $15,927,000 after purchasing an additional 20,091 shares in the last quarter. State of New Jersey Common Pension Fund D increased its stake in Alkermes by 15.1% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,677 shares of the company’s stock valued at $1,793,000 after purchasing an additional 8,214 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Alkermes by 1.3% in the second quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock valued at $1,249,000 after buying an additional 551 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $45 price target, signaling analyst conviction in upside versus the current level. Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation
• Neutral Sentiment: Alkermes announced a CEO succession plan: long‑time CEO Richard Pops will retire effective July 31, 2026 and EVP/COO Blair Jackson will become CEO on Aug. 1, 2026; Pops will remain chairman — provides leadership clarity but raises integration/execution questions ahead of the Avadel integration. Alkermes plc Announces CEO Succession Plan
• Neutral Sentiment: Company is presenting at upcoming conferences (TD Cowen) and recently closed the Avadel transaction, items investors should watch for slides/management commentary on integration and revenue contribution. Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Q4 results: Alkermes reported EPS of ~$0.29, below consensus (~$0.43) while revenue (~$384.6M) was roughly in line/slightly ahead of estimates but down ~10.6% year‑over‑year — an earnings miss that weighs on near‑term investor sentiment. Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 guidance was updated to a negative EPS range (‑0.798 to ‑0.680), far below Street expectations (consensus ~1.63), creating significant near‑term earnings uncertainty and likely driving most of the downward price pressure. Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
• Neutral Sentiment: Short‑interest data reported in some feeds appears inconsistent/invalid (zero/NaN values) and shouldn’t be relied on for a constructive signal today. Listen to Conference Call / View Press Release

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.